Health & Fitness
Health and Fitness
Health and Fitness
Wed, October 26, 2011
Tue, October 25, 2011
The Law Firm of Levi &;; Korsinsky Notifies Investors With Losses on Their Investment in K-V Pharmaceutical Company o
October 25, 2011 10:39 ET
The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in K-V Pharmaceutical Company of Class Action Lawsuit and the Deadline of December 19, 2011 to Seek a Lead Plaintiff Position
NEW YORK, NY--(Marketwire - Oct 25, 2011) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of K-V Pharmaceutical Company ("K-V" or the "Company") (
For more information, click here: [ http://zlk.9nl.com/k-v-pharmaceutical/ ].
The complaint alleges that K-V and certain of its officers and directors issued materially false and misleading statements regarding the miscarriage prevention drug "Makena." In particular, the complaint alleges that K-V made misleading statements indicating that the Company would expand access to Makena to low-income and other at-risk groups. According to the complaint, contrary to these statements, K-V increased the price of Makena 1490% to $1500 per injection, thus limiting the affordability of the treatment. Furthermore, the complaint alleges that K-V issued misleading statements indicating that the FDA had granted K-V the exclusive distribution rights over "Makena" and that the agency would enforce said rights by preventing the distribution of generic compounds by K-V's competitors. On March 30, 2011, the FDA issued a press release indicated that it would not "take enforcement action against pharmacies" that sold the generic form.
If you are a member of the class and suffered a loss in K-V stock, you have until December 19, 2011 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://www.zlk.com/k-v-pharmaceutical-kva.html ].
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
